AbbVie and the generic pharmaceutical Pool have signed a voluntary licensing agreement , enabling a generic version of the pharmaceutical company 's Mavyret hepatitis viral drug to be sold in poorer markets via royalty - free agreements with generic drug makers . However , the arrangement has been criticised for having limited availability in comparison with similar licensing agreements .
AbbVie and the Medicines Patent Pool have signed a voluntary licensing deal, enabling a generic version of the pharmaceutical company's Mavyret hepatitis C drug to be sold in poorer countries via royalty-free deals with generic drug makers. However, the arrangement has been criticised for having limited availability in comparison with similar licensing agreements.